VS2-370
Aggressive tumors (breast, lung, pancreas, hemato-oncology)
Pre-clinicalActive
Key Facts
Indication
Aggressive tumors (breast, lung, pancreas, hemato-oncology)
Phase
Pre-clinical
Status
Active
Company
About Virostatics
ViroStatics is a dual-focus biotechnology company with a core R&D pipeline targeting oncology and virology through selective kinase inhibitors, led by its clinical candidate Myrtleciclib. The company supplements its R&D efforts with a specialized contract testing service for respiratory viruses, operating from a BSL-3 facility. Founded and led by experienced biotech entrepreneur Dr. Franco Lori, the company is privately held, has secured EU and Italian research grants, and appears to be in a preclinical/early clinical stage, seeking partnerships for its drug assets.
View full company profile